Sveriges mest populÀra poddar
Flot.bio x Philip Hemme

Claus Crone Fuglsang, Novonesis đŸ‡©đŸ‡° | Biosolutions, Industrial biotech, Synbio | E53

1 tim 11 min‱17 februari 2026

Novonesis arose from a 2023 merger of Novozymes and Chr Hansen, and is a highly profitable powerhouse. CSO Claus talks about the applications of Novonesis’ technology, its low profile among consumers, and how hard it is for biosolutions startups to scale up.

⭐ ABOUT THE SPEAKER

Claus first joined Novozymes in 1993 and led its R&D both in Denmark and the US, with six years as CSO. He has a Master’s degree in biochemistry and an MBA.

🔗 LINKS MENTIONED



📜 TRANSCRIPT


Read the full transcript here: https://flot.bio/episode/claus-crone-fuglsang-novonesis-biosolutions/

💾 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐ SPONSORSHIP


Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

đŸ«¶ FOLLOW US

🙏 LIKE/FOLLOW/REVIEW


Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

đŸŽ™ïžABOUT FLOT.BIO


Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.

⏰ TIMESTAMPS

  • [00:00:00] Intro
  • [00:02:19] Novonesis: the Novozymes and Chr Hansen merger
  • [00:09:51] Under the consumer radar
  • [00:12:52] Business divisions and myriad applications
  • [00:20:46] The scaling challenge in biosolutions
  • [00:27:39] Novonesis’ profitability and growth
  • [00:36:34] Genetic engineering and cool patents
  • [00:47:57] Novonesis’ growing AI use
  • [00:56:34] Claus Crone Fuglsang’s enthusiasm for his work
  • [01:00:09] Industrial biotech globally
  • [01:04:15] Quick-fire questions

Flot.bio x Philip Hemme med Flot.bio finns tillgÀnglig pÄ flera plattformar. Informationen pÄ denna sida kommer frÄn offentliga podd-flöden.